Concentric Analgesics

Concentric Analgesics is a clinical-stage biotech developing a novel platform of non-opioid pain therapeutics. Its lead candidate, vocacapsaicin (CA-008), is a Phase 3-ready prodrug that converts to capsaicin to provide durable, localized pain relief without systemic side effects or numbness. The company aims to address significant unmet needs in postsurgical and chronic pain markets, targeting the reduction of opioid dependence and associated healthcare costs. Its pipeline also includes programs for cancer-related pain and osteoarthritis.

A platform of novel, water-soluble prodrugs that locally convert into potent TRPV1 agonists (like capsaicin) to provide long-lasting, site-specific analgesia without systemic side effects or numbness.

The non-opioid pain market is competitive, with players developing NGF antibodies (e.g., tanezumab), novel sodium channel blockers, and other targeted therapies. Concentric differentiates through its localized, prodrug approach aiming for long duration from a single dose without motor blockade, competing against both systemic drugs and short-acting local anesthetics.